Last reviewed · How we verify
STN1013800 ophthalmic solution
STN1013800 ophthalmic solution is a corticosteroid used to treat inflammation in the eye.
STN1013800 ophthalmic solution is a corticosteroid used to treat inflammation in the eye. Used for Treatment of non-infectious uveitis affecting the posterior segment of the eye.
At a glance
| Generic name | STN1013800 ophthalmic solution |
|---|---|
| Sponsor | Santen Pharmaceutical Co., Ltd. |
| Drug class | Corticosteroid |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
It works by suppressing the immune system's response to reduce inflammation and swelling in the eye. This can help to alleviate symptoms associated with conditions such as uveitis and other inflammatory eye diseases.
Approved indications
- Treatment of non-infectious uveitis affecting the posterior segment of the eye
Common side effects
- Increased intraocular pressure
Key clinical trials
- A Pharmacokinetics (PK) Study in Healthy Adults (EARLY_PHASE1)
- LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis. (PHASE3)
- A Study in Chinese Patients With Acquired Blepharoptosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- STN1013800 ophthalmic solution CI brief — competitive landscape report
- STN1013800 ophthalmic solution updates RSS · CI watch RSS
- Santen Pharmaceutical Co., Ltd. portfolio CI